IDO1 and hepatocellular carcinoma: IDO is chronically activated in many cancer patients [9] and its expression or enzyme activity correlates with a poor prognosis in patients with various cancers such as ovarian carcinoma [10], [11], endometrial carcinoma [12], [13], hepatocellular carcinoma [14] and colorectal carcinoma [15].